J&J Cautious On Sales Projections Pending FDA, CMS Decisions On ESAs

While awaiting FDA's final safety evaluation and Medicare's final coverage policy on erythropoeisis-stimulating agents, Johnson & Johnson will maintain a conservative stance on sales and earnings for the second half of the year